CRISPR / Gene Editing News

2026-10-16

Gene Editing Weekly — October 10–16, 2026: a base editor restores glucose production in GSDIa patients, and a census finds two individualized editing trials

Beam Therapeutics' in vivo base editor restored endogenous glucose production in six patients with glycogen storage disease type Ia, and a census of the clinical trial registry found two individualized editing constructs among 148 gene-editing studies.

CRISPR / Gene Editing News

Gene Editing Weekly — October 24–30, 2026: HG302 edits DMD in four boys and kills one at the high dose, and the FDA drafts a one-patient approval path

Gene Editing Weekly — October 17–23, 2026: a retrotransposon builds a CAR-T inside a mouse, and China's pathway counts 112 filed projects

Gene Editing Weekly — October 10–16, 2026: a base editor restores glucose production in GSDIa patients, and a census finds two individualized editing trials

Gene Editing Weekly — October 3–9, 2026: an in vivo prime editor reaches a patient, Editas clears its first human trial, and Caribou gives up on off-the-shelf CAR-T

Gene Editing Weekly — September 26–October 2, 2026: a base-editing trade-secrets suit, Germany's first Casgevy treatment, and a second route to fetal hemoglobin

Gene Editing Weekly — September 19–25, 2026: an AI find re-rates the sector, a prime-editing IND, and an epigenetic silencer for hepatitis B

Gene Editing Weekly — September 12–18, 2026: a first-in-disease gene therapy, a rolling IND pilot, and Cellectis's in vivo pivot

Gene Editing Weekly — September 5–11, 2026: Intellia enters priority review as multi-ethnic base editing reports 12-month durability

Gene editing weekly — August 29–September 4, 2026: One-year editing, $400 million runway, and the cost of delivery

Gene Editing Weekly — August 22–28, 2026: PBGENE-DMD enters the clinic as prime assembly stretches the payload envelope

Gene Editing Weekly — August 14–21, 2026: FDA's CGT guidance, Genglycos, and the editing quality-control stack

Gene Editing Weekly — August 7–14, 2026: a clinical edge case, safer editing tools, and Sangamo's asset sale

CRISPR / Gene Editing News

Gene Editing Weekly — October 24–30, 2026: HG302 edits DMD in four boys and kills one at the high dose, and the FDA drafts a one-patient approval path

Gene Editing Weekly — October 17–23, 2026: a retrotransposon builds a CAR-T inside a mouse, and China's pathway counts 112 filed projects

Gene Editing Weekly — October 10–16, 2026: a base editor restores glucose production in GSDIa patients, and a census finds two individualized editing trials

Gene Editing Weekly — October 3–9, 2026: an in vivo prime editor reaches a patient, Editas clears its first human trial, and Caribou gives up on off-the-shelf CAR-T

Gene Editing Weekly — September 26–October 2, 2026: a base-editing trade-secrets suit, Germany's first Casgevy treatment, and a second route to fetal hemoglobin

Gene Editing Weekly — September 19–25, 2026: an AI find re-rates the sector, a prime-editing IND, and an epigenetic silencer for hepatitis B

Gene Editing Weekly — September 12–18, 2026: a first-in-disease gene therapy, a rolling IND pilot, and Cellectis's in vivo pivot

Gene Editing Weekly — September 5–11, 2026: Intellia enters priority review as multi-ethnic base editing reports 12-month durability

Gene editing weekly — August 29–September 4, 2026: One-year editing, $400 million runway, and the cost of delivery

Gene Editing Weekly — August 22–28, 2026: PBGENE-DMD enters the clinic as prime assembly stretches the payload envelope

Gene Editing Weekly — August 14–21, 2026: FDA's CGT guidance, Genglycos, and the editing quality-control stack

Gene Editing Weekly — August 7–14, 2026: a clinical edge case, safer editing tools, and Sangamo's asset sale